CVRx Logo_R_RGB_black.png
CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
16 nov. 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
Imara-Logo-Color-RGB.jpg
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
08 nov. 2021 07h00 HE | Imara, Inc.
Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D.,...
CVRx Logo_R_RGB_black.png
CVRx Reports Third Quarter 2021 Financial and Operating Results
04 nov. 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, Nov. 04, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and...
Retrospective Analysis Using the VoluMetrix NIVA|HF Investigational Algorithm to Assess Patients With Heart Failure Predicts Hospitalization
04 nov. 2021 09h00 HE | VoluMetrix
NASHVILLE, Tenn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital monitoring to enhance well-being, today...
CVRx Logo_R_RGB_black.png
CVRx to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call
21 oct. 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
Logo.png
Emerging Drugs for the Heart Failure Treatment: A Focus on Recent Clinical Trials | DelveInsight
19 oct. 2021 20h00 HE | DelveInsight Business Research LLP
Los Angeles, USA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Emerging Drugs for the Heart Failure Treatment: A Focus on Recent Clinical Trials | DelveInsight The pipeline of Heart failure is robust, with...
CVRx Logo_R_RGB_black.png
CVRx Added to Russell 2000® and 3000® Indexes
17 sept. 2021 08h00 HE | CVRx, Inc.
MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and...
logo 02.jpg
Heart Failure POC and LOC Devices Market Worth USD 175.35 Million by 2027 at 16.2% - Report by Market Research Future (MRFR)
19 août 2021 12h00 HE | Market Research Future
New York, US, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Heart Failure POC & LOC Devices Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Heart...
CVRx Logo_R_RGB_black.png
CVRx Reports Second Quarter 2021 Financial and Operating Results
04 août 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and...
CVRx Logo_R_RGB_black.png
CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference
29 juil. 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...